Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US0029421007
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01223DLB2
AARD

Aardvark Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Software - Application · THEMEFOLIO: $HLTH
NAME
Aardvark Therapeutics Inc
ISIN
US0029421007
TICKER
AARD
MIC
XNAS
REUTERS
AARD.OQ
BLOOMBERG
AARD US
Fri, 27.02.2026       Aardvark Therapeutics

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimin...
Fri, 13.02.2026       Aardvark Therapeutics

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Wed, 10.12.2025       Aardvark Therapeutics

Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout...
Thu, 13.11.2025       Aardvark Therapeutics

Q32025 Earnings...
Tue, 11.11.2025       Aardvark Therapeutics

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on November 10, 2025, one new employee was gra...
Tue, 04.11.2025       Aardvark Therapeutics

New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment landscape ...
Mon, 03.11.2025       Aardvark Therapeutics

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that (i) on October 20, 2025, one new employee was granted an inducement award consisting o...
Tue, 23.09.2025       Aardvark Therapeutics

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the Stifel 2025 Virtual Cardiome...
Wed, 27.08.2025       Aardvark Therapeutics

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during...
Wed, 13.08.2025       Aardvark Therapeutics

SAN DIEGO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the second quarter ended June...
Silent Ad
Tue, 12.08.2025       Aardvark Therapeutics

SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced new positive preclinical data demonstrating the pot...
Fri, 18.07.2025       Aardvark Therapeutics

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that between July 8-14, 2025, two new employees were granted inducement awards consisting o...
Tue, 24.06.2025       Aardvark Therapeutics

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi...
Mon, 19.05.2025       Aardvark Therapeutics

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointments of key members of its leadership te...
Wed, 14.05.2025       Aardvark Therapeutics

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 3...
Mon, 31.03.2025       Aardvark Therapeutics

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December...